alendronate has been researched along with Hematochezia in 7 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Hematochezia: The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients receiving alendronate for osteoporosis carry a significantly higher risk of developing upper gastrointestinal bleeding (GIB) and lower GIB (hazard ratio 1." | 3.80 | Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study. ( Hou, MC; Hu, HY; Lee, FY; Lin, HC; Luo, JC; Peng, YL, 2014) |
| "Isolated case reports of gastric ulcers after alendronate sodium use raised concern about the gastroduodenal safety of daily alendronate." | 3.71 | Gastric and duodenal safety of daily alendronate. ( Andrade, SE; Beck, A; Boles, M; Buist, DS; Carey, VJ; Chan, KA; Chandler, JM; Chase, GA; Donahue, JG; Ettinger, B; Fishman, P; Goodman, M; Guess, HA; Gurwitz, JH; LaCroix, AZ; Levin, TR; Platt, R, 2002) |
| " Although these agents are generally well tolerated, serious gastrointestinal adverse events, including hospitalization for gastrointestinal bleed, may arise." | 1.35 | Comparative gastrointestinal safety of weekly oral bisphosphonates. ( Brookhart, MA; Cadarette, SM; Katz, JN; Levin, R; Solomon, DH; Stedman, MR; Stürmer, T, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peng, YL | 1 |
| Hu, HY | 1 |
| Luo, JC | 1 |
| Hou, MC | 1 |
| Lin, HC | 1 |
| Lee, FY | 1 |
| Connolly, JG | 1 |
| Gagne, JJ | 1 |
| Cadarette, SM | 1 |
| Katz, JN | 1 |
| Brookhart, MA | 1 |
| Stürmer, T | 1 |
| Stedman, MR | 1 |
| Levin, R | 1 |
| Solomon, DH | 1 |
| Katz, MH | 1 |
| Sawhney, MS | 1 |
| Nelson, DB | 1 |
| Kaye, PS | 1 |
| Donahue, JG | 1 |
| Chan, KA | 1 |
| Andrade, SE | 1 |
| Beck, A | 1 |
| Boles, M | 1 |
| Buist, DS | 1 |
| Carey, VJ | 1 |
| Chandler, JM | 1 |
| Chase, GA | 1 |
| Ettinger, B | 1 |
| Fishman, P | 1 |
| Goodman, M | 1 |
| Guess, HA | 1 |
| Gurwitz, JH | 1 |
| LaCroix, AZ | 1 |
| Levin, TR | 1 |
| Platt, R | 1 |
7 other studies available for alendronate and Hematochezia
| Article | Year |
|---|---|
Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study.
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2014 |
Comparison of Calipers for Matching on the Disease Risk Score.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conserva | 2016 |
Comparative gastrointestinal safety of weekly oral bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2009 |
Opportunities to decrease inappropriate uses of proton pump inhibitors: Comment on "Proton pump inhibitor use and the antifracture efficacy of alendronate".
Topics: Alendronate; Bone Density Conservation Agents; Denmark; Dose-Response Relationship, Drug; Drug Inter | 2011 |
Alendronate-induced colon ulcers: case report of a new clinical entity.
Topics: Aged; Alendronate; Biopsy; Cecal Diseases; Cecum; Colon; Colonic Diseases; Colonoscopy; Diagnosis, D | 2004 |
Gastric hemorrhage and ulceration in hiatal hernia sac associated with alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Esophageal Diseases; Female; Gastrointestinal Hemorrhage; Hern | 1999 |
Gastric and duodenal safety of daily alendronate.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Cohort Studies; Duodenal Diseases; Duodenal Ulcer; Fema | 2002 |